<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202020000300119</article-id>
<article-id pub-id-type="doi">10.29277/cardio.35.3.10</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hipertensión arterial y dislipemia]]></article-title>
<article-title xml:lang="en"><![CDATA[Arterial hypertension and dyslipidemia]]></article-title>
<article-title xml:lang="pt"><![CDATA[Hipertensão arterial e dislipidemia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[María Noel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiroz]]></surname>
<given-names><![CDATA[Luca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Spósito]]></surname>
<given-names><![CDATA[Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huarte]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Maciel  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>119</fpage>
<lpage>132</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202020000300119&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202020000300119&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202020000300119&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la enfermedad cardiovascular representa mundialmente la principal causa de muerte resultando imprescindible entonces un abordaje multifactorial mediante el cálculo del riesgo cardiovascular (RCV). Múltiples series a nivel mundial han demostrado una alta asociación entre hipertensión arterial (HTA) y dislipemia, en algunas superiores al 50%. El objetivo de este estudio es determinar la asociación entre ambas variables con el fin de profundizar en la estratificación de riesgo del paciente hipertenso.  Materiales y métodos: se realizó un estudio analítico, observacional, de tipo transversal, que incluyó a todos los pacientes que asistieron a la policlínica de HTA de nuestro centro entre el 2 de marzo de 2015 y el 2 de octubre de 2019 inclusive.  Resultados:  se incluyeron 103 pacientes. El 75,7% (n=78) presentó dislipemia. Se destaca que el 68,9% (n=71) presenta HTA nocturna. Se estableció una asociación estadísticamente significativa entre dislipemia e HTA nocturna, con OR=3,364. En cuanto al perfil lipídico, predomina la dislipemia mixta en un 37,9% (n=39).  Conclusiones:  existe una alta relación entre HTA y dislipemia. La HTA nocturna y el patrón non dipper asocian mayor RCV.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  cardiovascular disease represents the main cause of death worldwide. A multifactorial approach is essential, by calculating cardiovascular risk. Series worldwide have shown a high association between hypertension and dyslipidemia, in some of them higher than 50%. Our objective is to determine the association between both variables in order to improve the risk stratification of the hypertensive patient.  Materials and methods:  an analytical, observational, cross-sectional study was carried out, which included all the patients who attended the hypertension polyclinic between March 2, 2015 and October 2, 2019 inclusive.  Results:  75.7% (n=78) of the patients presented dyslipidemia. It is noteworthy that 68.9% (n=71) have nocturnal hypertension. A statistically significant association between dyslipidemia and nocturnal hypertension was established, with an OR=3.364. Regarding the lipid profile, mixed dyslipidemia predominates in 37.9%.  Conclusions:  there is a high relationship between hypertension and dyslipidemia. Nocturnal hypertension and the non-dipper pattern are associated with cardiovascular risk.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  as doenças cardiovasculares representam a principal causa de morte no mundo. Uma abordagem multifatorial é essencial, calculando o risco cardiovascular. As séries em todo o mundo demonstraram uma alta associação entre hipertensão e dislipidemia, em alguns superiores a 50%. Nosso objetivo é determinar a associação entre as duas variáveis, a fim de melhorar a estratificação de risco do paciente hipertenso.  Materiais e métodos:  foi realizado um estudo analítico, observacional e transversal, que incluiu todos os pacientes que compareceram à policlínica hipertensão entre 2 de março de 2015 e 2 de outubro de 2019 inclusive.  Resultados:  75,7% (n=78) dos pacientes apresentaram dislipidemia. Vale ressaltar que 68,9% (n=71) possuem hipertensão noturna. Foi estabelecida associação estatisticamente significante entre dislipidemia e hipertensão noturna, com OR=3,364. Quanto ao perfil lipídico, a dislipidemia mista predomina em 37,9%.  Conclusões:  existe uma alta relação entre hipertensão e dislipidemia. A hipertensão noturna e o padrão non dipper estão associados ao risco cardiovascular.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[Hipertensión arterial nocturna]]></kwd>
<kwd lng="es"><![CDATA[Patrón de variabilidad]]></kwd>
<kwd lng="es"><![CDATA[Dislipemia]]></kwd>
<kwd lng="en"><![CDATA[Arterial hypertension]]></kwd>
<kwd lng="en"><![CDATA[Nocturnal hypertension]]></kwd>
<kwd lng="en"><![CDATA[Variability pattern]]></kwd>
<kwd lng="en"><![CDATA[Dyslipidemia]]></kwd>
<kwd lng="pt"><![CDATA[Hipertensão arterial]]></kwd>
<kwd lng="pt"><![CDATA[Hipertensão noturna]]></kwd>
<kwd lng="pt"><![CDATA[Padrão de variabilidade]]></kwd>
<kwd lng="pt"><![CDATA[Dislipidemia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Stefanescu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The global epidemiology of hypertension]]></article-title>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>223-37</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Spiering]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Agabiti]]></surname>
</name>
<name>
<surname><![CDATA[Rosei]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azizi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 ESC/ESH guidelines for the management of arterial hypertension]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2018</year>
<volume>39</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>3021-104</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeron]]></surname>
<given-names><![CDATA[RMC]]></given-names>
</name>
<name>
<surname><![CDATA[Albuquerque]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension and cholesterol]]></article-title>
<source><![CDATA[Rev Assoc Med Bras]]></source>
<year>2019</year>
<volume>65</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1421-2</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piepoli]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Hoes]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Agewall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albus]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brotons]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cataplano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2016 European Guidelines on cardiovascular disease prevention in clinical practice the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>2315-81</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez Roca]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Moreno]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Llisterri]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Matalí]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Característica de la presión arterial en una población de dislipémicos española asistida en atención primaria Estudio LIPICAPPA]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2007</year>
<volume>60</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>825-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<source><![CDATA[Manual nacional de abordaje del tabaquismo en el primer nivel de atención (Internet)]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[MSP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[D'Alessio]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Fradkin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kernan]]></surname>
<given-names><![CDATA[WN]]></given-names>
</name>
<name>
<surname><![CDATA[Mathieu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mingrone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hyperglycemia in type 2 diabetes, 2018 A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2018</year>
<volume>41</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2669-701</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definición y clasificación de obesidad]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2012</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>124-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mach]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baigent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Koskinas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Casula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Badimon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 ESC/EAS Guidelines for the management of dyslipidaemias lipid modification to reduce cardiovascular risk]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>111-88</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Flaxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Danaei]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shibuya]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Adair- Rohani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9859</numero>
<issue>9859</issue>
<page-range>2224-60</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Spósito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Llorrens]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Casuística en pacientes asistidos en una policlínica]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2019</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>163-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[W-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Melgarejo]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Thijs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Boggia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of office and ambulatory blood pressure with mortality and cardiovascualr outcome]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2019</year>
<volume>322</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>409-20</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Sierra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gorostidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baneja]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de La Cruz]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rui Lope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nocturnal Hypertension or non dipper which is better associated with the Cardiovascular Risk profile?]]></article-title>
<source><![CDATA[Am J Hyperten]]></source>
<year>2014</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>680-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendizábal]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Llorens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nava]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension in metabolic syndrome vascular pathophysiology]]></article-title>
<source><![CDATA[Int J Hypertens]]></source>
<year>2013</year>
<volume>2013</volume>
<page-range>1-15</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marotta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vía]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Disfunción endotelial.En: Artagaveytia N, Bianchi S, Cayota A. Tema de patología médica]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Oficina del Libro]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
